FBXO32 and dilated cardiomyopathy: The aim of this study was to clarify whether the myostatin/AKT/FOXO pathway as well as the expression of MAFbx and MuRF1 are changed in dilated cardiomyopathy of ischemic origin (IDCM) and dilated cardiomyopathy of non-ischemic origin (NIDCM) compared to a control group.